Clinical Study

S1p Ich Ancillary Study

Posted Date: Oct 3, 2019

  • Investigator: Kyle Walsh
  • Specialties: Emergency Medicine, Stroke
  • Type of Study: Observational/Survey

BAF312 is an international, randomized clinical trial aimed to determine the safety and efficacy of Siponimod for the treatment of ICH. Patients are randomized 1:1 to siponimod or placebo of the trial. Patient demographics, medical co-morbidities, ICH size, location, and characteristics, treatments, complications, and clinical outcomes are rigorously collected. The proposed substudy integrates several investigations on neuroimmune mechanisms on the pathophysiology of brain injury after ICH into the infrastructure provided by the trial. Peripheral blood samples will be collected from patients enrolled in BAF312 on enrollment (day 1), day 3, and day 7.

Criteria:

Patients Are Enrolled As Part Of The Novartis Funded Clinical Trial Clinical Trial Protocol Cbaf312x2207: A Phase Ii, Patient And Investigator Blinded, Randomized, Placebo-Controlled Study To Evaluate Efficacy, Safety And Tolerability Of Baf312 In Patients With Stroke Due To Intracerebral Hemorrhage (Ich). All Inclusion/Exclusion Criteria Are Standardized By The Main Clinical Trial, Not This Substudy.

Keywords:

Baf312, Cbaf312x2207, Ichseq-S1p

For More Information:

Jacqueline Davis
513-558-5359
davis2jq@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.